Merck gets approval for its CRISPR genome-editing technology in China
Category: #health  By Dhananjay Punekar  Date: 2018-04-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck gets approval for its CRISPR genome-editing technology in China

Merck KGaA has declared that the Chinese Patent Office has provided it with the right to use its CRISPR gene-editing technology in the country. According to the company’s statement, the CRISPR technique helps chromosomes to alter in the living cells and is one of the modern therapies that can be used for treating many of the chronic disorders.

The firm also seems to have added that the new technology is used to determine the genes associated with cancer along with other rare ailments including reverse mutations causing blindness in the individuals. Udit Batra, CEO of Life Sciences division at Merck KGaA, has stated that the firm will license its CRISPR-linked patents to companies involved in carrying out pure scientific research activities, offering therapeutic solutions, and making use of farming technology.

As per reliable sources, Merck has filed patents for using its CRISPR technology across countries such Japan, Brazil, U.S., and India. Regions such as South Korea, Israel, Australia, Canada, Europe, and Singapore have already approved the patents for the use of CRISPR technology for treating various diseases. The firm’s forthcoming CRISPR technology patent in China includes chromosomal integration or cutting sequence of chromosomes from the eukaryotic cell tissues along with the insertion of donor DNA sequence into these Eukaryotic cells by using the gene-editing CRISPR technique.

The genome-editing technology assists the researchers to replace disease linked gene mutation with a beneficial DNA gene sequence. Merck has claimed that the CRISPR gene-editing technology can be utilized to add transgenes to the endogenous protein materials, helping them in visual tracking of the disease within the cells.

The firm, which is involved in both the deployment and supply of the genome editing CRISPR Technology, holds the view that the new technique has resulted in many of the technological breakthroughs witnessed lately across the medical and biotechnology sectors. Apparently, Merck supports the gene-editing applications and complies with the ethical & legal standards that regulate gene-editing technology.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...